Sun, Dec 28, 2014, 10:53 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • zzzdq zzzdq Feb 19, 2002 7:50 PM Flag

    AVI Execs. to speak at Roth conference

    Tuesday February 19, 6:57 pm Eastern Time
    Press Release
    SOURCE: AVI BioPharma Inc.
    AVI BioPharma Executives to Speak at Roth Capital Partners and BIO CEO Investor Conferences
    PORTLAND, Ore.--(BW HealthWire)--Feb. 19, 2002--AVI BioPharma Inc. (Nasdaq:AVII - news; Nasdaq:AVIIW - news; Nasdaq:AVIIZ - news) today announced that company executives will speak at two prominent investor and biotechnology conferences this week.

    AVI's President and Chief Operating Officer, Alan Timmins, will present today at the Roth Capital Partners Growth Stock Conference in Laguna Niguel, Calif., and Denis Burger, Ph.D., the company's chief executive officer, will present at the BIO CEO and Investor Conference on Thursday, Feb. 21, in New York City.

    Burger and Timmins will discuss the company's progress with its two core technology platforms: NEUGENE� antisense and cancer immunotherapy. In addition, both executives will demonstrate the broad applicability and versatility of these two platforms -- as well as market and partnership opportunities.

    ``AVI is the only company that is in clinical development with novel third-generation antisense technology that can address a variety of life-threatening diseases,'' Burger said. ``Our approach bypasses the lengthy process most drug companies must undergo to develop a drug to block the disease-causing gene. This puts us in a great position to develop new therapies and add significant value to therapies currently marketed.''

    Speaking times for Timmins and Burger are as follows:


    14th Annual Roth Capital Partner Growth Stock Conference
    The Ritz-Carlton, Laguna Niguel, Calif., Feb. 18-20, 2002
    Speaker: Alan Timmins, President and COO
    Date: Feb. 19, 2002
    Time: 5 p.m. PT
    BIO CEO and Investor Conference

    Walldorf-Astoria, New York City, Feb. 20-22, 2002

    Speaker: Denis Burger, CEO

    Date: Feb. 21, 2002

    Time: 5:20 p.m. ET

    AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using two technology platforms: NEUGENE antisense drugs and cancer immunotherapy. Its lead cancer agent, AVICINE� a therapeutic cancer vaccine, has completed three Phase II trials in colorectal and pancreatic cancer and is in a Phase III pivotal trial in colorectal cancer. The first application of its NEUGENE compounds, Resten-NG, is designed to treat cancer, cardiovascular restenosis and other cell proliferation disorders by inhibiting the production of a cellular transcription factor, the oncogene c-myc. It is currently in Phase II trials for restenosis and in Phase I/II trials for cancer and polycystic kidney disease. More information about AVI is available on the Company's Web site at http://www.avibio.com/.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • wherestherestofthismoose wherestherestofthismoose Feb 19, 2002 9:02 PM Flag

      This news means nothing. Roth Capital as far as I know is an unimportant firm (at least in Avi's future). The conference in NY is a more influencial one. But there's a lot of companies there, and we're going to hear the same things we always hear. Some new news would be good!

    • what does this part refer to:

      ``AVI is the only company that is in clinical development with novel third-generation antisense technology that can address a variety of life-threatening diseases,'' Burger said.

      ``Our approach bypasses the lengthy process most drug companies must undergo to develop a drug to block the disease-causing gene.

      This puts us in a great position to develop new therapies and add significant value to therapies currently marketed.''

      • 1 Reply to dbl_wide2002
      • >what does this part refer to:

        Lemmie try to translate:

        ``AVI is the only company that is in clinical development with novel third-generation antisense technology that can address a variety of life-threatening diseases,'' Burger said.

        We have mo betta technology (it should make perfect anti-sense to everybody by now...).

        ``Our approach bypasses the lengthy process most drug companies must undergo to develop a drug to block the disease-causing gene.

        Anti-c-myc alone is good for many indications. Also, once we establish the safety of our morpholino chemistry, we can move straight into efficacy trials with new compounds with different sequences.

        This puts us in a great position to develop new therapies and add significant value to therapies currently marketed.''<

        Currently marketed? Well, what else if not p-450 cytochrome???!!!

        If this is what I think it is, hiring that big PR firm makes perfect anti-sense, too <VBG>.

        Together with the good news from IDEC/FDA we may have a sunny day tomorrow...

 
SRPT
13.92+0.04(+0.29%)Dec 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
PG&E Corporation
NYSEFri, Dec 26, 2014 4:02 PM EST
Rice Energy Inc.
NYSEFri, Dec 26, 2014 4:02 PM EST